Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Deferred Revenue (2021 - 2025)

Ocular Therapeutix (OCUL) has 8 years of Current Deferred Revenue data on record, last reported at $14.0 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 10837.5% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $14.0 million, up 10837.5%, while the annual FY2025 figure was $14.0 million, 10837.5% up from the prior year.
  • Current Deferred Revenue reached $14.0 million in Q4 2025 per OCUL's latest filing, roughly flat from $14.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $14.4 million in Q4 2023 and bottomed at $128000.0 in Q4 2024.
  • Average Current Deferred Revenue over 5 years is $6.9 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: plummeted 99.11% in 2024, then skyrocketed 10837.5% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $13.0 million in 2021, then plummeted by 95.57% to $576000.0 in 2022, then soared by 2398.26% to $14.4 million in 2023, then tumbled by 99.11% to $128000.0 in 2024, then surged by 10837.5% to $14.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $14.0 million in Q4 2025, $14.0 million in Q3 2025, and $14.0 million in Q2 2025.